Tamoxifen for women at high risk of breast cancer

Breast Cancer: Targets and Therapy

Volumn 6, Issue , 2014, Pages 29-36

  Nazarali, Safia A ^a   Narod, Steven A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Chemoprevention; Tamoxifen; Women

Indexed keywords

AFIMOXIFENE; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; EXEMESTANE; FENRETINIDE; KI 67 ANTIGEN; LIPID; PLACEBO; RALOXIFENE; SOMATOMEDIN; TAMOXIFEN;

ATTITUDE; ATYPICAL DUCTAL HYPERPLASIA; BINDING AFFINITY; BREAST CANCER; BREAST DENSITY; CANCER INCIDENCE; CATARACT; DEEP VEIN THROMBOSIS; DENSITY; DRUG DOSE REDUCTION; DRUG METABOLISM; ENDOMETRIUM CANCER; ENDOMETRIUM TUMOR; FAMILY HISTORY; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAMMOGRAPHY; META ANALYSIS (TOPIC); MORTALITY; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; AGE; BONE PAIN; CANCER RISK; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE MUTATION; HEART FAILURE; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MENOPAUSAL SYNDROME; PATIENT ATTITUDE; PHYSICIAN ATTITUDE;

EID: 84898801100     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S43763     Document Type: Review

References (33)

1. Brown K. Breast cancer chemoprevention: risk-benefit effects of the anti-oestrogen tamoxifen. Expert Opin Drug Saf. 2002;1:253-267.
2. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365: 1687-1717.
3. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351: 1451-1467.
4. National Institute for Health and Care Excellence. Major shift in breast cancer care on horizon as NICE recommends preventative drugs for 'at-risk' women. Available from: http://www.nice.org.uk/newsroom/pressreleases/NICERecommendsBreastCancerdrugs.jsp. Accessed November 27, 2013.
5. Higgins MJ, Stearns V. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010;12:7-15.
6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2005;97: 1652-1662.
7. Nayfield SG, Karp JE, Ford LG, et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991;83:1450-1459.
8. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283-290.
9. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272-282.
10. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy. J Natl Cancer Inst. 2007;99:727-737.
11. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol. 2010;7:702-707.
12. Gronwald J, Tung N, Foulkes WD, et al; Hereditary Breast Cancer Clinical Study Group. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118:2281-2284.
13. Metcalfe K, Lynch H, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22: 2328-2335.
14. Phillips KA, Milne R, Rookus M, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31:3091-3099.
15. King MC, Wieand S, Hale K, et al; National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA. 2001;286:2251-2256.
16. Whiffen A, El-Tamer M, Taback B, Feldman S, Joseph KA. Predictors of breast cancer development in women with atypical ductal hyperplasia and atypical lobular hyperplasia. Ann Surg Oncol. 2011;18:463-467.
17. Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136:627-633.
18. Cuzick J, Warwick J, Pinney E, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst. 2011;103:744-752.
19. Chen J-H, Change Y-C, Chang D, et al. Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: preliminary study. Magn Reson Imaging. 2011;29:91-98.
20. Iqbal J, Ginsburg OM, Wijeratne TD, et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev. 2012;38:318-328.
21. Smith LL, Brown K, Carthew P, et al. Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit Rev Toxicol. 2000;30: 571-594.
22. Kaplan CP, Kim SE, Wong ST, Sawaya GF, Walsh JM, Pérez-Stable EJ. Willingness to use tamoxifen to prevent breast cancer among diverse women. Breast Cancer Res Treat. 2012;133:357-366.
23. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res. 2011;4:1360-1365.
24. Armstrong K, Quistberg DA, Micco E, et al. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med. 2006;166:2260-2265.
25. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3:696-706.
26. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31: 2942-2962.
27. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364: 2381-2391.
28. Van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet. 2011;377:321-331.
29. Lazzeroni M, Serrano D, Dunn BK, et al. Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res. 2012;14:214.
30. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst. 1998;90: 1461-1467.
31. Decensi A, Robertson C, Guerrieri-Gonzaga A, et al. Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol. 2009;27:3749-3756.
32. Alkner S, Bendahl P-O, Ferno M, et al. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial. Eur J Cancer. 2009;45:2496-2502.
33. Rouanet P, Linares-Cruz G, Dravet F, et al. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J Clin Oncol. 2005;23:2980-2987.